MyHep All™ (28 tabs) is a licensed generic of Epclusa® (Sofosbuvir/Velpatasvir) produced in an FDA approved factory in India. It’s a direct-acting antiviral prescription medication for the treatment of chronic Hepatitis C across all genotypes in patients with or without liver cirrhosis (compensated). For the majority of patients, 12 weeks (3 bottles) of treatment is needed to reach cure. But for treatment experienced genotype 3 patients or for all patients with advanced Liver cirrhosis (decompensated), treatment duration is 24 weeks (6 bottles). Epclusa® is approved by the FDA and EMA for use in adults and children aged six years and older or weighing at least 37 pounds (17 kilograms).
- Epclusa® overall established cure rate across all 6 strains of Hepatitis C is roughly 96%
- Epclusa® side effects profile is quite mild especially with enough water intake
- Consult a doctor before concurrent administration of other drugs and supplements
Active Ingredients : Sofosbuvir 400 mg / Velpatasvir 100 mg
Produced by Mylan Pharmaceuticals® of the United States (US FDA approved manufacturer)